ADMA Biologics (NASDAQ:ADMA) Director Jerrold Grossman Purchases 12,500 Shares of Stock

ADMA Biologics Inc (NASDAQ:ADMA) Director Jerrold Grossman bought 12,500 shares of the stock in a transaction on Monday, May 11th. The stock was purchased at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the acquisition, the director directly owned 501,384 shares of the company’s stock, valued at $4,016,085.84. The trade was a 2.56% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

ADMA Biologics Stock Up 6.7%

ADMA opened at $8.41 on Wednesday. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51. The firm has a market cap of $2.00 billion, a P/E ratio of 12.37 and a beta of 0.83. ADMA Biologics Inc has a 52 week low of $7.21 and a 52 week high of $22.37. The business’s fifty day simple moving average is $11.68 and its 200 day simple moving average is $15.33.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, meeting analysts’ consensus estimates of $0.19. The business had revenue of $114.49 million for the quarter, compared to analyst estimates of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The business’s revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter last year, the company earned $0.11 earnings per share. As a group, equities research analysts anticipate that ADMA Biologics Inc will post 0.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ADMA shares. Zacks Research lowered ADMA Biologics from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 27th. Wall Street Zen lowered ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Canaccord Genuity Group decreased their price objective on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Mizuho decreased their price objective on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $19.00.

Hedge Funds Weigh In On ADMA Biologics

Several large investors have recently added to or reduced their stakes in the business. Lido Advisors LLC raised its holdings in shares of ADMA Biologics by 3.8% in the 4th quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company’s stock worth $312,000 after purchasing an additional 629 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in shares of ADMA Biologics by 11.7% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 6,063 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 634 shares during the period. Cim LLC raised its holdings in shares of ADMA Biologics by 0.7% in the 3rd quarter. Cim LLC now owns 91,486 shares of the biotechnology company’s stock worth $1,341,000 after purchasing an additional 665 shares during the period. Smartleaf Asset Management LLC raised its holdings in shares of ADMA Biologics by 28.9% in the 2nd quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 700 shares during the period. Finally, Clearstead Advisors LLC raised its holdings in shares of ADMA Biologics by 55.7% in the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 795 shares during the period. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.